Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:22:03 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:ESPR from 2023-05-04 to 2024-05-03 - 44 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-29 08:00U:ESPRNews ReleaseEsperion to Participate in Upcoming May Investor Conferences
2024-04-23 08:00U:ESPRNews ReleaseEsperion to Report First Quarter 2024 Financial Results on May 7
2024-04-07 14:45U:ESPRNews ReleaseEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL(TM) (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
2024-04-01 08:00U:ESPRNews ReleaseEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
2024-03-26 08:00U:ESPRNews ReleaseEsperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 16:00U:ESPRNews ReleaseEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
2024-03-22 15:10U:ESPRNews ReleaseU.S. FDA Approves Broad New Labels for NEXLETOL(TM) and NEXLIZET(TM) to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
2024-03-22 11:05U:ESPRNews ReleaseCHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
2024-02-27 06:00U:ESPRNews ReleaseEsperion Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-16 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-13 08:00U:ESPRNews ReleaseEsperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
2024-02-01 14:00U:ESPRNews ReleaseRFK, Esperion Therapeutics Announce 2024 Promotional Schedule
2024-01-23 16:00U:ESPRNews ReleaseEsperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters ¢ € ™ Option to Purchase Additional Shares
2024-01-18 21:16U:ESPRNews ReleaseEsperion Announces Pricing of $85.1 Million Public Offering of Common Stock
2024-01-18 16:00U:ESPRNews ReleaseEsperion Announces Proposed Public Offering of Common Stock
2024-01-03 07:00U:ESPRNews ReleaseEsperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
2023-12-18 08:00U:ESPRNews ReleaseEsperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 16:00U:ESPRNews ReleaseU.S. FDA Updates LDL-C Lowering Indication for Esperion ¢ € ™s NEXLETOL ‚ ® (bempedoic acid) Tablet and NEXLIZET ‚ ® (bempedoic acid and ezetimibe) Tablet
2023-11-13 10:30U:ESPRNews ReleaseEsperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
2023-11-11 11:00U:ESPRNews ReleasePartners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
2023-11-09 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-11-07 06:00U:ESPRNews ReleaseEsperion Reports Third Quarter 2023 Financial Results
2023-10-31 08:00U:ESPRNews ReleaseEsperion to Participate in Jefferies London Healthcare Conference
2023-10-24 08:00U:ESPRNews ReleaseEsperion to Report Third Quarter 2023 Financial Results on November 7
2023-09-12 10:15U:ESPRNews ReleaseAmerican College of Cardiology Program to Increase Cholesterol Screenings
2023-08-28 08:00U:ESPRNews ReleaseEsperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
2023-08-26 11:00U:ESPRNews ReleaseEsperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
2023-08-11 08:00U:ESPRNews ReleaseTwo CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
2023-08-08 16:15U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-08-01 06:00U:ESPRNews ReleaseEsperion Reports Second Quarter 2023 Financial Results
2023-07-24 08:00U:ESPRNews ReleaseEsperion to Participate in BTIG Virtual Biotechnology Conference 2023
2023-07-17 06:00U:ESPRNews ReleaseEsperion to Report Second Quarter 2023 Financial Results on August 1
2023-07-07 08:00U:ESPRNews ReleaseEsperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
2023-06-28 08:00U:ESPRNews ReleaseEsperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) ‚  for NILEMDO ‚ ® (bempedoic acid) Tablet and NUSTENDI ‚ ® (bempedoic acid and ezetimibe) Tablet
2023-06-24 14:30U:ESPRNews ReleaseEsperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
2023-06-15 14:30U:ESPRNews ReleaseEsperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
2023-06-08 08:00U:ESPRNews ReleaseEsperion to Present New Key Science at the American Diabetes Association ¢ € ™s 83rd Scientific Sessions 2023
2023-06-05 08:00U:ESPRNews ReleaseEsperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
2023-06-01 08:00U:ESPRNews ReleaseEsperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL ‚ ® (bempedoic acid) Tablet and NEXLIZET ‚ ® (bempedoic acid and ezetimibe) Tablet
2023-05-25 16:30U:ESPRNews ReleaseEsperion Announces Adjournment of 2023 Annual Meeting of Stockholders
2023-05-24 08:00U:ESPRNews ReleaseEsperion to Participate in Jefferies Healthcare Conference
2023-05-12 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-09 07:00U:ESPRNews ReleaseEsperion Reports First Quarter 2023 Financial Results
2023-05-04 08:30U:ESPRNews ReleaseEsperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9